Ga-DPI-4452 PET/CT outperforms FDG PET/CT in clear cell RCC
A prospective multicenter study in 68 patients with renal cell carcinoma compared [Ga]Ga-DPI-4452 PET/CT, which targets carbonic anhydrase IX, against [F]FDG PET/CT. In the clear cell RCC subgroup, the study reported diagnostic accuracy of 98.2% versus 76.8%, higher lesion detection (97.9% versus 47.1%), and greater tumor-to-background contrast, with clinical management changes occurring in 37.5% of patients using the new tracer versus 1.8% with FDG; no adverse events were observed.
Most relevant for: Patients with clear cell renal cell carcinoma undergoing staging, surveillance, or evaluation for suspected recurrent or metastatic disease.
Read the original at Journal of Nuclear MedicineSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More nuclear medicine updates
- New PET-based method images Ac-225 therapy with higher SNR than SPECTSep 30, 2026
- Open-Source Deep Learning Pipeline Automates PET-Only Tumor SegmentationSep 30, 2026
- New PET tracer targets human CD68 to image macrophagesSep 28, 2026
- PSMA-PET detects more oligometastatic prostate cancer than conventional imagingSep 28, 2026
- Quantitative flow by CZT-SPECT predicts cardiovascular events independentlySep 25, 2026